Researcher Saul Priceman brings CAR T clinical trials to patients with solid tumor cancers

September 18, 2018 | Letisia Marquez

Saul Priceman, Ph.D., an assistant research professor with City of Hope’s T Cell Immunotherapy Laboratory, is focused on developing more CAR T clinical trials for patients battling solid tumor cancers like breast and prostate cancer.

Continue Reading

Ph.D. candidate leads groundbreaking study for neurodegenerative disease

October 17, 2018 | Maxine Nunes

Li Li's work, as a Ph.D. candidate at City of Hope, with Alexander disease may also shed new light on similar neurodegenerative conditions such as Parkinson’s, Alzheimer’s, and amyotrophic lateral sclerosis.

New therapy shows promise for melanoma metastasized to the brain

October 1, 2018 | Maxine Nunes

Oncologist Kim Margolin, M.D., brings new hope to people with melanoma that has metastasized to the brain with a remarkable new study.

Solving the mystery of cutaneous lymphoma

September 30, 2018 | Abe Rosenberg

City of Hope dermatologist Christiane Querfeld, M.D., Ph.D., and her team may have uncovered the underlying cause of a stubborn form of lymphoma

CIRM Awards City of Hope Researchers $3.7 million to Develop Glioblastoma Clinical Trial

September 28, 2018 | Letisia Marquez

California Institute for Regenerative Medicine has awarded City of Hope $3.7 million to develop a phase 1 clinical trial for glioblastoma patients, which would genetically alter blood stem cells to better tolerate chemotherapy.

TGen tackles diabetic blindness with new collaboration

September 25, 2018 | City of Hope

City of Hope affiliate TGen has been awarded a $2.8 million grant in an effort to discover new treatments for diabetic retinopathy.

Researcher Saul Priceman brings CAR T clinical trials to patients with solid tumor cancers

September 18, 2018 | Letisia Marquez

Saul Priceman, Ph.D., an assistant research professor with City of Hope’s T Cell Immunotherapy Laboratory, is focused on developing more CAR T clinical trials for patients battling solid tumor cancers like breast and prostate cancer.

New Study: Bifunctional JMDJ1B gene controls cell fate decision of blood progenitors

May 23, 2018 | Samantha Bonar

Diseases like cancer arise due to both changes in gene expression and cellular function. One important factor regulating gene expression and cellular function is called epigenetic modifications. Epigenetic modifications are inheritable changes not associated with changes in the DNA sequence.

City of Hope's CEACAM Research Comes Full Circle with New CAR T Approach

February 9, 2018 | Jyoti Madhusoodanan

More than 50 years after its discovery, CEA remains one of the most widely used clinical markers of cancer. As the diverse roles of CEA and its family members, known as CEA-related cell adhesion molecules (CEACAMs), have grown clearer, researchers at City of Hope are working on a new wave of clinical tools and therapies.